IL‐15 has been used clinically in tumor therapy, where it recruits CD8+ T cells and NK cells to the tumor site, leading to the secretion of XCL1 and the subsequent attraction of dendritic cells expressing XCR1 receptors. Here, XCL1 is linked to neoplasm.